bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.06.22.497072

Replicable multivariate BWAS with moderate sample sizes

Abstract

Brain-Wide Association Studies (BWAS) have become a dominant method for linking mind and brain over the past 30 years. Univariate models test tens to hundreds of thousands of brain voxels individually, whereas multivariate models ( multivariate BWAS) integrate signals across brain regions into a predictive model. Numerous problems have been raised with univariate BWAS, including lack of power and reliability and an inability to account for pattern-level information embedded in distributed neural circuits1-3. Multivariate predictive models address many of these concerns, and offer substantial promise for delivering brain-based measures of behavioral and clinical states and traits2,3. In their recent paper4, Marek et al. evaluated the effects of sample size on univariate and multivariate BWAS in three large-scale neuroimaging dataset and came to the general conclusion that "BWAS reproducibility requires samples with thousands of individuals". We applaud their comprehensive analysis, and we agree that (a) large samples are needed when conducting univariate BWAS of individual differences in trait measures, and (b) multivariate BWAS reveal substantially larger effects and are therefore more highly powered. However, we disagree with Marek et al.s claims that multivariate BWAS provide "inflated in-sample associations" that often fail to replicate (i.e., are underpowered), and that multivariate BWAS consequently require thousands of participants when predicting trait-level individual differences. Here we substantiate that (i) with appropriate methodology, the reported in-sample effect size inflation in multivariate BWAS can be entirely eliminated, and (ii) in most cases, multivariate BWAS effects are replicable with substantially smaller sample sizes (Figure 1). O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=198 SRC="FIGDIR/small/497072v1_fig1.gif" ALT="Figure 1"> View larger version (44K): org.highwire.dtl.DTLVardef@180764borg.highwire.dtl.DTLVardef@d64a2forg.highwire.dtl.DTLVardef@a0865aorg.highwire.dtl.DTLVardef@d4b14c_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 1.C_FLOATNO Multivariate BWAS provide unbiased effect sizes and high replicability with low-moderate sample sizes. (a) In-sample effects in multivariate BWAS are only inflated if estimates are obtained without cross-validation. (b) Cross-validation fully eliminates in-sample effect size inflation and, as a consequence, provides higher replicability. Each point in (a) and (b) corresponds to one bootstrap subsample, as in Fig. 4b of Marek et al. Dotted lines denote the threshold for p=0.05 with n=495. (c) The inflation of in-sample effect size obtained without cross-validation (red) is reduced, but does not disappear, at higher sample sizes. Conversely, cross-validated estimates (blue) are slightly pessimistic with low sample sizes and become quickly unbiased as sample size is increased. (d) Without cross-validation, in-sample effect size estimates are non-zero (r{approx}0.5, red) even when predicting permuted outcome data. Cross-validation eliminates systematic bias across all sample sizes (blue). Dashed lines in (c) and (d) denote 95% parametric confidence intervals, and shaded areas denote bootstrap and permutation-based confidence intervals. (e-f) Cross-validated analysis reveals that sufficient in-sample power (e) and out-of-sample replication probability (P(rep)) (f) can be achieved for a variety of phenotypes at low or moderate sample sizes. 80% power and P(rep) are achievable in <500 participants for half the phenotypes tested (colored bars) using the prediction algorithm in Marek et al. (top panels in (e) and (f), sample size required for 80% power or P(rep) shown). Other phenotypes require sample sizes >500 (bars with arrows). Power and P(rep) can be substantially improved with a ridge regression-based model recommended in some comparison studies10,11 (bottom panels in (e) and (f)), with 80% power and P(rep) with sample sizes as low as n=100 and n=75, respectively, when predicting cognitive ability, and sample sizes between 75 and 375 for other investigated variables, except inhibition assessed with the flanker task. (g) We estimated interactions between sample size and publication bias by computing effect size inflation (rdiscovery - rreplication) only for those bootstrap cases where prediction performance was significant (p>0.05) in the replication sample. Our analysis shows that the effect size inflation due to publication bias is modest (<10%) with <500 participants for half the phenotypes using the Marek et al. model and all phenotypes but the flanker using the ridge model. C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Spisak, T., Bingel, U., Wager, T. D.. 2022-06-26. Replicable multivariate BWAS with moderate sample sizes. https://doi.org/10.1101/2022.06.22.497072

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗